Cannabis stocks soared after Trump may reclassify marijuana. Lower danger level boosts industry optimism significantly. Canopy Growth and Tilray Brands saw major stock surges.
DEA delays cannabis rescheduling until December 2024, impacting regulatory clarity. Decision now postponed past the presidential election, affecting market sentiment. Uncertainty may lead to declines in cannabis stock valuations, including CGC.